BRVE Braveheart Bio
Braveheart Bio earnings company data as of 4:49 AM ET 10/24
History
2 periods, newest first. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 8 Dec | EPS | — | — | — |
| Rev | — | — | — | ||
| FY2026 Q2 | 8 Sep | EPS | 2.69 | — | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by BRVE's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $159M bought by 10 insiders
- None no sales outside a trading plan
- None no planned (10b5-1) sales
-
AH Bio Fund IV, L.P. 10% owner, +3 joint filersBuy$19.8M 1,100,000 shares at $18.00 +12% to stakeTraded Aug 7 Filed Aug 11
-
Erez Chimovits DirectorBuy$34.9M 1,940,000 shares at $18.00 New stakeTraded Aug 7 Filed Aug 11
-
James Paul Rickey CFOBuy$500K 27,777 shares at $18.00 +5.6% to stakeTraded Aug 7 Filed Aug 7
-
Christopher Viehbacher DirectorBuy$1.5M 83,333 shares at $18.00 +16% to stakeTraded Aug 7 Filed Aug 7
-
David I Malek DirectorBuy$75K 4,166 shares at $18.00 +0.8% to stakeTraded Aug 7 Filed Aug 7
-
Michele A. Anderson Chief Development OfficerBuy$20K 1,111 shares at $18.00 +0.3% to stakeTraded Aug 7 Filed Aug 7
-
David Charles Lubner DirectorBuy$1M 55,555 shares at $18.00 New stakeTraded Aug 7 Filed Aug 7
-
Forbion Growth Opportunities Fund III Cooperatief U.A. 10% owner, +3 joint filersBuy$64.8M 3,600,000 shares at $18.00Traded Aug 7 Filed Aug 7
Also filed in the last 12 months, not counted as buying or selling: 6 conversions.
SEC filings
Recent issuer filings from EDGAR, 10 shown.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.